BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10023310)

  • 21. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
    Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
    J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
    Connolly EA; Weickhardt A; Grimison P; Asher R; Heller GZ; Lewin J; Liow E; Toner G; Tung ILY; Tran B; Hill S; Walpole E; McKenzie J; Kuchel A; Goh J; Forgeson G; Tan A; Joshi A; Wickham A; Tan H; Wang Y; Winstanley MA; Hamad N; Wong V
    BJU Int; 2022 Jun; 130 Suppl 1():5-16. PubMed ID: 35355402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.
    Lorch A; Neubauer A; Hackenthal M; Dieing A; Hartmann JT; Rick O; Bokemeyer C; Beyer J
    Ann Oncol; 2010 Apr; 21(4):820-825. PubMed ID: 19822531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
    Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
    Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors.
    Suleiman Y; Siddiqui BK; Brames MJ; Abonour R; Einhorn LH
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):161-3. PubMed ID: 22892555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O; Siegert W; Beyer J
    Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases.
    Papiani G; Einhorn LH
    Bone Marrow Transplant; 2007 Aug; 40(3):235-7. PubMed ID: 17563738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer.
    Bhatia S; Abonour R; Porcu P; Seshadri R; Nichols CR; Cornetta K; Einhorn LH
    J Clin Oncol; 2000 Oct; 18(19):3346-51. PubMed ID: 11013274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
    Gerl A; Clemm C; Schmeller N; Hartenstein R; Lamerz R; Wilmanns W
    Br J Cancer; 1996 Oct; 74(8):1280-5. PubMed ID: 8883418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
    De Giorgi U; Demirer T; Wandt H; Taverna C; Siegert W; Bornhauser M; Kozak T; Papiani G; Ballardini M; Rosti G;
    Ann Oncol; 2005 Jan; 16(1):146-51. PubMed ID: 15598952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose chemotherapy for relapsed testicular germ cell tumours.
    Chovanec M; Adra N; Abu Zaid M; Abonour R; Einhorn L
    Nat Rev Urol; 2023 Apr; 20(4):217-225. PubMed ID: 36477219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.